Profund Advisors’s TG Therapeutics TGTX Stock Holding History

Profund Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.01M	Sell	36,513 -39,526	-52%	-$1.62M	0.06%	197
2026 Q1	$2.53M	Buy	76,039 +1,225	+2%	+$36.5K	0.09%	151
2025 Q4	$2.23M	Buy	74,814 +24,569	+49%	+$802K	0.07%	197
2025 Q3	$1.82M	Buy	50,245 +5,803	+13%	+$191K	0.06%	209
2025 Q2	$1.6M	Buy	44,442 +2,057	+5%	+$76.6K	0.06%	220
2025 Q1	$1.67M	Sell	42,385 -25,638	-38%	-$863K	0.07%	206
2024 Q4	$2.05M	Sell	68,023 -3,618	-5%	-$104K	0.07%	179
2024 Q3	$1.68M	Buy	71,641 +9,025	+14%	+$197K	0.06%	224
2024 Q2	$1.11M	Sell	62,616 -23,180	-27%	-$370K	0.04%	275
2024 Q1	$1.3M	Sell	85,796 -7,693	-8%	-$123K	0.05%	284
2023 Q4	$1.6M	Sell	93,489 -50,092	-35%	-$582K	0.07%	228
2023 Q3	$1.2M	Buy	143,581 +87,133	+154%	+$1.21M	0.07%	241
2023 Q2	$1.4M	Sell	56,448 -33,956	-38%	-$877K	0.08%	229
2023 Q1	$1.36M	Buy	+90,404	New	+$1.37M	0.08%	209

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Profund Advisors's TGTX Position: Q2 2026 in Review

Profund Advisors reduced its TG Therapeutics (TGTX) stake by 52% in Q2 2026, selling an estimated $1.62M and leaving 36,513 shares worth $2.01M. The position accounts for 0.06% of the portfolio, ranked #197.

Profund Advisors first reported a position in TGTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.53M in Q1 2026. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Profund Advisors held 36,513 shares of TG Therapeutics worth $2.01M as of Q2 2026.
Profund Advisors sold 39,526 TG Therapeutics shares in Q2 2026, an estimated $1.62M.
TG Therapeutics made up 0.06% of Profund Advisors's portfolio in Q2 2026, its #197 holding.
Profund Advisors first reported a position in TG Therapeutics in Q1 2023 and has held it in 14 quarters since.
Profund Advisors's TG Therapeutics position peaked at $2.53M in Q1 2026.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.